TNF and rheumatoid arthritis: Moreover, the FDA-approved next generation of JAK inhibitors(upadacitinib, baricitinib, tofacitinib), IL-6 receptor antagonists(sarilumab, tocilizumab), and TNF blockers (golimumab, certolizumabpegol, adalimumab, infliximab, etanercept) present emerging optionsfor RA treatment.